Recombinant Human ERBB2 Protein (Ser22-Thr652), C-6×His-tagged
Product Description
Cat
IMP-9565
Official Symbol
ERBB2
Product Overview
Recombinant human ErbB2/Her2 protein (Ser22-Thr652), with a C-terminal 6×His tag was expressed in Human embryonic kidney cell.
Description
This gene encodes a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. This protein has no ligand binding domain of its own and therefore cannot bind growth factors. However, it does bind tightly to other ligand-bound EGF receptor family members to form a heterodimer, stabilizing ligand binding and enhancing kinase-mediated activation of downstream signalling pathways, such as those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase. Allelic variations at amino acid positions 654 and 655 of isoform a (positions 624 and 625 of isoform b) have been reported, with the most common allele, Ile654/Ile655, shown here. Amplification and/or overexpression of this gene has been reported in numerous cancers, including breast and ovarian tumors. Alternative splicing results in several additional transcript variants, some encoding different isoforms and others that have not been fully characterized.
Expression System
HEK293
Species
Human
Tag
C-6×His
Predicted N Terminal
Ser22
Form
Lyophilized from a 0.2 μm filtered solution in PBS.
Molecular Mass
Predicted Molecular Mass: 70 kDa
SDS-PAGE: 93-108 kDa, under reducing conditions
Protein length
Ser22-Thr652
Bio-activity
Measured by its ability to block anti-ErbB2 mediated inhibition of SK-BR-3 human breast cancer cell proliferation. Brodowicz, T. et al. (1997) Int. J. Cancer 73:875. The ED50 for this effect is 0.3-1.2 μg/mL in the presence of 0.6 μg/mL Human ErbB2/Her2 Antibody.
Endotoxin
<0.10 EU/μg of the protein by the LAL method.
Purity
>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie Blue Staining.
Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70 centigrade as supplied.
1 month, 2 to 8 centigrade under sterile conditions after reconstitution.
3 months, -20 to -70 centigrade under sterile conditions after reconstitution.
Reconstitution
Reconstitute at 500 μg/mL in PBS.
Bioactivity-ELISA 1
Bioactivity

Measured by its ability to block anti-ErbB2 mediated inhibition of SK-BR-3 human breast cancer cell proliferation. Brodowicz, T. et al. (1997) Int. J. Cancer 73:875. The ED50 for this effect is 0.3-1.2 μg/mL in the presence of 0.6 μg/mL Human ErbB2/Her2 Antibody.

Data Sheet MSDS
For research or industrial raw materials, not for personal medical use!

Online Inquiry
Contact Info